Proteonomix entered into a deal to conduct the clinical trial with the University of Miami, under which the University was required to pay expenses associated with the clinical study and the company was required to assist financially with the clinical study.
Proteonomix president Michael Cohen said UMK-121 pharmaceutical therapy is advancing toward its first human clinical trial in ESLD (‘End Stage Liver Disease’) patients and the company intends to provide patients with alternatives.
"We believe that the commercialization of this technology can provide Proteonomix with significant revenue potential," Cohen added.